The AIEOP-BFM ALL 2000 study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as PCR targets (PCR-MRD), at two time points (TP), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n=3184) 
Introduction
Over the past three decades, remarkable advances have been achieved in the treatment of acute lymphoblastic leukemia (ALL) in children. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, significant challenges still remain. In fact, although current treatment strategies result in long-term remission for nearly 80% of children with ALL, the remaining 20% ultimately relapse, and cure rate after relapse is around 25-40%.
Moreover, some subgroups of children who now receive intensive therapy are likely to be overtreated and may well be cured using less intensive regimens, this resulting in reduced toxicity and less long-term side effects. [10] [11] [12] Besides risk factors associated with the patient (e.g., gender, age at diagnosis) and the disease (e.g., white blood cell count at diagnosis, immunophenotype, structural and numeric chromosomal aberrations), measurement of in vivo treatment effectiveness has proven to be most important in predicting patient outcome and risk of relapse. 4, [13] [14] [15] [16] [17] [18] Over the past 10 to 15 years, several techniques have been developed to complement and refine morphology in assessing response to treatment, including immunologic or molecular markers, fluorescent in situ hybridization (FISH), in vitro drug response and colony assays. [19] [20] [21] [22] [23] [24] This technological advancement led to introducing the concept of minimal residual disease (MRD), which has challenged the conventional definition of "remission".
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Several studies on childhood and adult ALL, mainly based on immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements as PCR targets for monitoring MRD, have indicated that the detection of residual disease during initial cytotoxic treatment can predict outcome. 13, 17, 21 Groups collaborating in the International "Berlin-Frankfurt-Münster" Study Group (I-BFM-SG) have pioneered the evaluation of MRD by PCR in childhood ALL. MRD assessment at day 33 and day 78 of treatment by two clonal Ig/TCR markers, with sensitivity of at least 10 -4 , identified three risk groups. MRD-based stratification was superior to that based on other clinically relevant risk factors, including age, blast count at diagnosis, and immunophenotype. 13 The collaborative-prospective AIEOP-BFM ALL 2000 study of childhood ALL (carried out in Austria, Germany, Italy and Switzerland) was based on these results. The laboratory requirements and feasibility results of the MRD-directed risk stratification using real-time, quantitative PCR analysis of Ig/TCR gene rearrangements, as applied in this large multi-center prospective trial, have been recently published. 19 In this paper, we report on the clinical results, and the predictive value For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Complete Remission (CR) was defined as the absence of physical signs of leukemia or detectable leukemia cells on blood smears, a bone marrow with active hemopoiesis and fewer than 5% leukemia blast cells, and normal cerebrospinal fluid. Patients who did not achieve CR at the end of induction phase IA were treated with phase IB of Protocol I and three subsequent High Risk (HR) blocks; resistance was defined as failure to achieve CR by the end of the third HR block (see suppl.
Materials and Methods

Patients
Figure 1 and suppl. Table 1 for protocol details).
Molecular marker identification and MRD analysis
The logistics of the study, cell sample isolation and identification of the markers for MRD based on clinical parameters, to the HR group; these patients are not part of this report.
Treatment protocol
All enrolled patients were treated according to the AIEOP-BFM ALL 2000 study protocol:
treatment outlines, details and differences between AIEOP and BFM are shown in supplementary 
Results
The cohort of 4016 children between 1 and 18 years of age with newly diagnosed Ph -pB ALL, enrolled in the AIEOP-BFM ALL 2000 study, had a 7-year EFS (SE) and Survival (SE) of 80.4%(0.9) and 91.8%(0.5), respectively.
The 3184 children stratified by MRD had, by definition, completed induction phase IA (TP1) and induction consolidation phase IB (TP2). This report only focuses on these patients, alive at TP2
(day +78).
Their overall 7-year estimates for EFS (SE) and survival (SE) were 80.7% ( The distribution of disease and patient characteristics by PCR-MRD stratification is shown in Table   2 . Patients with hyperleukocytosis (WBC ≥ 100,000/µl) or PPR had higher probability of being confirms this observation.
In each subgroup described in Table 2 , patients had significantly different EFS by MRD levels (p<0.001).
According to AIEOP-BFM ALL 2000 final stratification, 167 patients were allocated to HR treatment (due to PPR or MLL/AF4 fusion or no CR at day +33) although their MRD was at SR (n=37) or IR (n=130). Interestingly, the outcome of these patients was favorable: the 5-year-EFS of Figure 2 shows the prognostic value of MRD in subgroups defined by genetic features. In TEL/AML1 positive patients (n=762; 25.9% of pB-ALL), high levels of MRD at TP2 were rarely detected (n=10; 1.3%); yet MRD was able to stratify the remaining patients in two large subgroups (57.7% MRD-SR; 40.9 % MRD-IR) with significantly different outcome (Figure 2a) . Similar results were obtained in patients with favorable DNA-index (equal to or greater than 1.16 and less than 1.6): patients at MRD-HR were rare (1.4%); MRD-SR and IR patients had significantly different outcome (Figure 2b ).
Fifty-four Ph
+ ALL patients treated in our study and stratified by MRD are here analysed separately, as it is of major interest to evaluate whether MRD response discriminates outcome also in these patients who are generally considered at dismal prognosis 35, 36 . Ph Superiority of PCR-MRD over conventional stratification criteria can also be shown by evaluating its impact in patients of the AIEOP-BFM ALL 2000 study after stratifying them according to the BFM 95 criteria 6 (based on age, WBC count, early morphological response and clonal translocations; Table 2 ). 3% and 4.8% of patients respectively at SR and IR by BFM 95 criteria were MRD-HR, and these patients had an unfavorable prognosis ( Results obtained by applying the Cox model to single characteristics (univariate analysis) are contrasted to those obtained in the multivariate analysis (Table 3) . Except for the increased risk of relapse in PPR patients, which is not significant (HR=1.37, 95% CI= 0.95-1.99), all other characteristics affect the hazard of relapse significantly. In particular, PCR-MRD has by far the strongest prognostic value, with a 4-fold and 9-fold increase in relapse rate for IR and HR, respectively, as compared to SR levels.
The multivariate analysis confirms the prognostic value of PCR-MRD and shows that WBC count, TEL/AML1 status and DNA index retain independent significant impact on the hazard of relapse.
Interestingly, PPR is now associated to a borderline significant lower risk of relapse. For the interpretation of these results, many aspects should be considered. First of all, PPR (compared to PGR) is still related to a higher probability of having PCR-MRD HR levels (Table 2) , which explains the higher relapse rate in univariate analysis (Table 3) . However, Kaplan-Meier analysis (Table 2) shows that PPR loses completely its adverse prognostic value if compared with PGR who have the same PCR-MRD levels (SR, IR, HR). This is not true, for instance, for higher WBC counts which, within the same PCR-MRD levels, still retain a worse outcome (Table 2 ). In the multivariate Cox model, the paradoxical result of a protective effect of PPR comes from adjusting for PCR-MRD, as well as for other features. Finally, it should also be considered that PPR is the only feature, among those included in the Cox model that, besides PCR-MRD, qualifies patients for the most intensive treatment arm, which evidently plays a role in improving these patients outcome. 6 can easily be discriminated into three new risk groups by MRD measured at two time points. The same pattern is observed within ALL NCI-subgroups. 34 Results reported here confirm that, in pB-ALL, MRD negativity at the end of induction (TP1) is the strongest predictor for excellent outcome (5-year-EFS >90%), so that it might be different in the future to plan randomized studies for improving outcome in MRD-SR patients.
Interestingly, among 1358 MRD-SR patients, only 61 relapsed, and 29 of them presented with an extramedullary either isolated (n=17) or combined (n=12) relapse, which may be, especially for the isolated ones, not likely to be predicted by bone marrow MRD response. High levels of MRD at TP2 are predictive for poor outcome (5-year EFS <50%), with a 5-year cumulative incidence of relapse (SE) of 27.8% (4.7) and 43.5% (6.4) in patients presenting PCR-MRD levels of 10 -3 or > 10 -3 respectively (Suppl. Table 2 ). Interestingly, however, while among patients presenting high MRD levels at TP1, those with no PCR-MRD detectable at TP2 had a favourable outcome, those with PCR-MRD still present at TP2 had a marked increase in the risk of relapse (Figure 4 ). These
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From findings show that TP2 PCR-MRD levels are very important to tailor treatment in patients with high PCR-MRD levels at TP1. In the multivariate analysis (Table 3) , PCR-MRD is, by far, the most relevant factor discriminating prognosis. It overshadows the importance of other known prognostic features, although WBC count at diagnosis, TEL/AML1 status and DNA index retain independent value. Noticeably, PPR appears associated to a decreased hazard of relapse which makes sense only considering that all PPR patients were allocated to HR treatment, regardless of any other features.
Although the MRD prognostic value is also therapy dependent, in our opinion these results may provide some hints for other studies, too. A favourable prognosis in all patients with fast clearance particularly if levels of MRD were high 4 or 5 weeks after diagnosis. Reduction of treatment intensity instead, in our opinion, should only be performed under controlled conditions. Such MRDbased risk algorithms are, however, still to some extent treatment dependent, and cannot universally be applied in every available ALL treatment regimen.
Measurement of MRD is widely applied in contemporary childhood ALL studies. The technologies used may be either molecular or flow-cytometric (FCM) and these two approaches may differ for sensitivity, specificity, costs, reproducibility and feasibility. 45 Standardization, reproducibility and quality control among different laboratories is absolutely necessary for both methodologies.
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In our study we used very strict criteria for patient stratification (at least two targets with a sensitivity of at least 10 The choice of the MRD methodology for a childhood ALL study depends largely on the aims of the study and resources available. The two methodologies (e.g. molecular biology and flow cytometry) could in fact be used also in a complementary fashion for different aims within the same study. As recently shown in a study conducted by AIEOP 46 , measurement of FCM-MRD on bone marrow samples collected on day 15, as already suggested by PCR-MRD findings at day 15 47 , may allow to identify very early responders (<0.1% blast cells), who may benefit from treatment reduction, as well as a small subset of patients with high MRD levels (≥10% blast cells) who have a poor prognosis independently of PCR-MRD response and could thus benefit from treatment intensification. Accordingly, in the AIEOP-BFM ALL 2009 study, these two groups of patients will be eligible for a randomized treatment reduction study and for HR treatment, respectively.
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